

Claims 27-29 depend from claims 19, 20 and 22, respectively, and further delineate the ligand binding portion recited in claims 19, 20 and 22 as comprising the amino acid sequence of Tyr26 to Asp839 of SEQ ID NO: 13. Support for claims 23-29 are found throughout the specification, particularly at page 7, line 28 to page 8, line 6; page 16, lines 14-16; page 34, lines 5-9 (describing the Y26-D839 portion of NR2); page 35, lines 22-26 (describing the expression of such receptor portion in COS cells); and page 40-41 (describing the binding of such receptor portion to leptin).

Applicants respectfully submit that the foregoing amendments do not introduce new subject matter. Attached hereto is a marked-up copy of the amendment to the specification and the claims, captioned "**Version with Markings to Show Changes Made.**"

It is respectfully submitted that the present case is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,


Frank S. DiGilio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/XZ:ab

Serial No.: TO BE ASSIGNED

Version with Markings to Show Changes Made

IN THE SPECIFICATION:

Please insert the following paragraph at page 1, line 3:

--CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of Serial No. 09/043,816, filed on September 17, 1998.--

IN THE CLAIMS:

Please cancel claims 1-5 and 12-14 without prejudice.

Please add the following claims:

23. A polypeptide fragment of the recombinant haemopoietin receptor according to any one of claims 6-11, wherein said polypeptide fragment binds leptin.

24. The polypeptide fragment according to claim 23, comprising the amino acid sequence of Tyr26 to Asp839 of SEQ ID NO: 13.

25. An antibody to the polypeptide fragment of claim 23.

26. An antibody to the polypeptide fragment of claim 24.

27. The method of claim 19, wherein said ligand binding portion comprises the amino acid sequence of Tyr26 to Asp839 of SEQ ID NO: 13.

28. The pharmaceutical composition of claim 20, wherein said ligand binding portion comprises the amino acid sequence of Tyr26 to Asp839 of SEQ ID NO: 13.

29. The method of claim 22, wherein said ligand binding portion comprises the amino acid sequence of Tyr26 to Asp839 of SEQ ID NO: 13.